ELI LILLY & CO (LLY) 342.57 -1.58 (-0.46%)
342.57 -1.58 (-0.46%)
US5324571083 - Common Stock - Premarket: 335.8 -6.77 (-1.98%)
Fundamental Rating
Overall LLY gets a fundamental rating of 5 out of 10. We evaluated LLY against 261 industry peers in the Pharmaceuticals industry. While LLY has a great profitability rating, there are some minor concerns on its financial health. While showing a medium growth rate, LLY is valued expensive at the moment.
Profitability
Profitability Rating
LLY's Return On Equity of 59.91% is amongst the best returns of the industry. LLY outperforms 85% of its industry peers. The industry average return on equity is 20.44%.
LLY has a very good Piotroski-F score of 8.00. This indicates a great health and profitability for LLY.
LLY has a Return On Assets of 12.71%. This is comparable to the industry average of 9.69%.
LLY's Profit Margin of 20.63% is in line with the rest of the industry. The industry average Profit Margin is 18.55%.
VS Industry
ROA (12.71%) VS Industry: 60% outperformed.
0.97
111.39
ROE (59.91%) VS Industry: 85% outperformed.
1.97
178.77
Profit Margin (20.63%) VS Industry: 60% outperformed.
2.50
1,952.78
Valuation
Valuation Rating
The Price/Earnings Ratio is 40.35, which means the current valuation is very expensive for LLY.
Compared to an average industry Price/Earning Ratio of 13.58, LLY is valued more expensive than its industry peers. On top of this 93% of the companies listed in the same industry are cheaper than LLY!
With a Forward Price/Earnings Ratio of 37.08, LLY is valued very expensively.
The high PEG Ratio, which compensates the Price/Earnings for growth, indicates LLY does not grow enough to justify the current Price/Earnings ratio.
With a price book ratio of 33.58, LLY is valued rather expensively.
Compared to an average industry price book ratio of 1.50, LLY is valued more expensive than its industry peers. 98% of the companies listed in the same industry are valued cheaper.
When comparing the Enterprise Value to EBITDA ratio of LLY to the average industry ratio of 11.35, LLY is valued more expensive than its industry peers. 88% of the companies listed in the same industry are valued cheaper.
VS Industry
Price/Earnings (40.35) VS Industry: 7% outperformed.
112.77
0.02
Price/Book (33.58) VS Industry: 2% outperformed.
540.61
0.13
Enterprise Value/ EBITDA (34.57) VS Industry: 12% outperformed.
258.44
0.25
Growth
Growth Rating
LLY shows quite a strong growth in Earnings Per Share. Measured over the last 5 years, the EPS has been growing by 18.34% yearly.
Based on estimates for the next 5 years, LLY will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.90% on average per year.
LLY is expected to show quite a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 11.67% yearly.
When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
LLY shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.71%.
When comparing the EPS growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is stable.
LLY shows a small growth in Revenue. In the last year, the Revenue has grown by 5.34%.
The Revenue has been growing slightly by 5.94% on average over the past 5 years.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | 18.34% | 13.69% | 0.71% | -3.85% | 6.35% | 14.91% | 17.9% |
| Revenue | 5.94% | 9.63% | 5.34% | 2.09% | 3.66% | 8.11% | 11.67% |
Health
Health Rating
LLY has an Altman-Z score of 6.98. This indicates that LLY is financially healthy and little risk of bankruptcy at the moment.
LLY has one of the better Altman-Z scores in its industry. It is much better than the industry average of -0.37. LLY has a better score than 82% of its industry peers.
The Piotroski-F score of LLY is 8.00. This is a very strong score and indicates great health and profitability for LLY.
LLY has a Current Ratio of 1.13. This is a normal value and indicates that LLY is financially healthy and should not expect problems in meeting its short term obligations.
When comparing the Current Ratio of LLY to the average industry Current Ratio of 3.49, LLY is less able to pay its short term obligations than its industry peers. 85% of its industry peers have a better Current Ratio.
A Quick Ratio of 0.88 indicates that LLY may have some problems paying its short term obligations.
When comparing the Quick Ratio of LLY to the average industry Current Ratio of 2.84, LLY is less able to pay its short term obligations than its industry peers. 84% of its industry peers have a better Quick Ratio.
Compared to an average industry Debt to Equity Ratio of 0.00, LLY is requires more financing than its industry peers. 91% of its industry peers have a better Debt to Equity Ratio.
VS Industry
Debt/Equity (1.4) VS Industry: 9% outperformed.
59.36
0.00
Quick Ratio (0.88) VS Industry: 16% outperformed.
-2.73
76.82
Current Ratio (1.13) VS Industry: 15% outperformed.
0.10
76.82
Altman-Z (6.98) VS Industry: 82% outperformed.
-244.28
84.57
Dividend
Dividend Rating
The dividend of LLY is nicely growing with an annual growth rate of 14.75%!
LLY has paid a dividend for at least 10 years, which is a reliable track record.
LLY has a Yearly Dividend Yield of 1.31%.
LLY pays out 56.76% of its income as dividend. This is a bit on the high side, but may be sustainable.
With a Dividend Yield of 1.31, LLY pays less dividend than the industry average, which is at 2.85. 83% of the companies listed in the same industry pay a better dividend than LLY!
Compared to an average S&P500 Dividend Yield of 2.41, LLY's dividend is way lower than the S&P500 average.
The dividend of LLY is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
VS Industry
Dividend Yield (1.31%) VS Industry: 17% outperformed.
0.71
7.11
ELI LILLY & CO342.57
NYSE:LLY (2/1/2023, 7:25:37 PM)-1.58 (-0.46%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Pharmaceuticals | ||
| Earnings (Last) | 11-01 2022-11-01/bmo | Earnings (Next) | 02-02 2023-02-02 |
| Inst Owners | 80.23% | Inst Owner Change | -0.1% |
| Ins Owners | 10.56% | Ins Owner Change | -0.89% |
| Market Cap | 338.16B | Analysts | 80 |
| Price Target | 397.31 (15.98%) | ||
| Dividend Yield | 1.31% | Dividend Growth | 14.75% |
| DP | 56.76% | Ex-Date | 02-14 2023-02-14 (1.13) |
| EPS beat(2) | 1 | Avg EPS beat(2) | -12.22% |
| Min EPS beat(2) | -26.71% | Max EPS beat(2) | 2.27% |
| EPS beat(4) | 3 | Avg EPS beat(4) | -1.52% |
| Min EPS beat(4) | -26.71% | Max EPS beat(4) | 18.07% |
| Revenue beat(2) | N/A | Avg Revenue beat(2) | -3.2% |
| Min Revenue beat(2) | -6.12% | Max Revenue beat(2) | -0.28% |
| Revenue beat(4) | 2 | Avg Revenue beat(4) | 0.21% |
| Min Revenue beat(4) | -6.12% | Max Revenue beat(4) | 4.79% |
| PT rev (1m) | 0.45% | PT rev (3m) | 11.54% |
| EPS NQ rev (1m) | 0% | EPS NQ rev (3m) | -9.85% |
| EPS NY rev (1m) | 0% | EPS NY rev (3m) | -2.25% |
| Revenue NQ rev (1m) | 0% | Revenue NQ rev (3m) | -2.32% |
| Revenue NY rev (1m) | 0% | Revenue NY rev (3m) | -0.5% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.35 | ||
| Fwd PE | 37.08 | ||
| P/S | 11.57 | ||
| P/FCF | 63.34 | ||
| P/OCF | 44.14 | ||
| P/B | 33.58 | ||
| P/tB | N/A | ||
| EV/EBITDA | 34.57 |
| EPS(TTM) | 8.49 | EY | 2.48% |
| EPS(NY) | 9.24 | Fwd EY | 2.7% |
| FCF(TTM) | 5.41 | FCFY | 1.58% |
| OCF(TTM) | 7.76 | OCFY | 2.27% |
| SpS | 29.62 | BVpS | 10.2 |
| TBVpS | -0.96 | PEG (NY) | N/A |
| PEG (5Y) | 2.2 | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.71% | ||
| ROE | 59.91% | ||
| ROIC | 23.74% | ||
| ROICexc | 25.98% | ||
| ROICexgc | 41.83% | ||
| OM | 29.29% | ||
| PM | 20.63% | ||
| GM | 75.61% |
| ROICexgc(3y) | 33.07% | ROICexcg growth 3Y | 17.44% |
| ROICexcg growth 5Y | 9.5% | ROICexc(3y) | 20.45% |
| ROICexc growth 3Y | 3.15% | ROICexc growth 5Y | 8.56% |
| OM growth 3Y | -0.33% | OM growth 5Y | 7.88% |
| PM growth 3Y | 9.44% | PM growth 5Y | 8.85% |
| GM growth 3Y | -1.75% | GM growth 5Y | 0.22% |
| F-Score | 8 | Asset Turnover | 0.62 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.4 | ||
| Debt/FCF | 2.98 | ||
| Debt/EBITDA | 1.56 | ||
| Cap/Depr | 145.78% | ||
| Profit Quality | 88.49% | ||
| Current Ratio | 1.13 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | 6.98 |
| F-Score | 8 | WACC | 8.41% |
| ROIC/WACC | 4.97 | Cap/Depr(3y) | 128.04% |
| Cap/Depr(5y) | 141.95% | Profit Quality(3y) | 70.19% |
| Profit Quality(5y) | N/A | ||
| EPS 1Y | 0.71% | EPS 3Y | 13.69% |
| EPS 5Y | 18.34% | EPS growth Q2Q | 2.06% |
| EPS Next Y | -3.85% | EPS Next 2Y | 6.35% |
| EPS Next 3Y | 14.91% | EPS Next 5Y | 17.9% |
| Revenue growth 1Y | 5.34% | Revenue growth 3Y | 9.63% |
| Revenue growth 5Y | 5.94% | Revenue growth Q2Q | 2.49% |
| Revenue Next Year | 2.09% | Revenue Next 2Y | 3.66% |
| Revenue Next 3Y | 8.11% | Revenue Next 5Y | 11.67% |
| EBIT growth 1Y | 14.52% | EBIT growth 3Y | 9.27% |
| EBIT growth 5Y | 14.28% | EBIT Next Year | 10.09% |
| EBIT Next 3Y | 19.49% | EBIT Next 5Y | 20.67% |
| FCF growth 1Y | 4.43% | FCF growth 3Y | 29.06% |
| FCF growth 5Y | 7.46% | OCF growth 1Y | 15.24% |
| OCF growth 3Y | 9.54% | OCF growth 5Y | 8.4% |
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA